LINC01194 and neoplasm: Regarding a tumor biomarker, molecular target expression (e.g., PD-L1), inflammation state (e.g., Myeloid-Derived Suppressive Cells, tertiary lymphoid structures, tumor-infiltrating lymphocytes), and tumor antigen expression (e.g., tumor mutational burden, microsatellite instability) are the most frequently tested markers.